Generic versions of the GLP-1 drug Ozempic have entered pharmacies across Canada at a lower price point [1, 2].
The arrival of generic semaglutide provides a more affordable alternative for patients who previously spent hundreds of dollars per month on brand-name treatments for diabetes and weight loss [1, 3].
Health Canada approved the first generic version of the medication on April 28, 2024 [2]. Following this approval, the drug began arriving at select pharmacy locations during the first week of May 2024 [1, 2].
Patients can now find the generic medication at various locations across the country, including select Shoppers Drug Mart and Rexall pharmacies [1, 3]. The cost for the generic version is roughly $100 per month [1].
This rollout comes amid rising competition within the GLP-1 drug market [2]. By introducing a low-cost alternative, the healthcare system aims to increase accessibility for those who require the medication but cannot afford the premium pricing of the original brand [1, 3].
“Generic versions of the GLP-1 drug Ozempic have entered pharmacies across Canada at a lower price point.”
The entry of generic semaglutide into the Canadian market marks a shift in the accessibility of GLP-1 medications. By reducing the monthly cost to approximately $100, the barrier to entry for chronic weight management and diabetes treatment is lowered, likely increasing patient adherence and reducing the financial burden on individuals and provincial health budgets.
